All Things Newz
Law \ Legal

A Look Ahead In Life Sciences: What We Are Tracking In Q1 2023 And Beyond – Life Sciences, Biotechnology & Nanotechnology


To print this article, all you need is to be registered or login on

As the life sciences industry continues to expand and grow
increasingly complex, so does its legal regulatory, and compliance
landscape. To help companies and investors navigate the many
evolving and emerging laws and regulations across pharmaceuticals,
biologics, drug development, medical devices and technology, and
diagnostics, our Life Sciences Regulatory team has provided a
comprehensive list of developments. We will update this list on an
ongoing basis throughout the year.


Preclinical & Clinical Research

How companies develop their products:

FDA Approval

Deciding whether a company can market or sell a specific


  • We will continue to see the use of real-world evidence
    in submissions, including likely continued guidance from FDA.
    Section 3629 of the [omnibus law] requires FDA to issue and/or
    update its guidance within one year. (US)

Medical Device/Medtech

In Vitro Diagnostic/Laboratory Testing

  • We expect forthcoming guidance
    from FDA on medical devices that fall within enforcement policies
    and Emergency Use Authorizations (EUAs) issued during the COVID-19
    Public Health Emergency. (US)

  • Note: The Omnibus Spending Law did not include
    the VALID Act, covering FDA regulation of laboratory developed
    tests (LDTs). (US)

Notable Regulatory Approval Updates Outside the United

  • We highlight the January 2023 formal proposed
    issued by the European Parliament and Council
    extending the Medical Device Regulation implementation period,
    slated for acceptance in early 2023. (EU)

  • We expect to see and plan to follow an early 2023 EU pilot program
    implementation for expert panel assistance to orphan and
    breakthrough device manufacturers. (EU)

Commercial FDA Requirements

How companies manufacture, promote, and monitor their
approved products:

  • FDA’s quality
    management system regulations
    with ISO 13485. (US)

  • We will see FDA implement its newly expanded authority
    under section 2511 of the Omnibus Spending Law for registration of
    foreign manufacturers contributing to products, such as those
    performing processing steps, producing ingredients or components,
    to register with the FDA. (US)

  • Section 3611 of the Omnibus Spending Law expands FDA’s
    authority over medical device inspections to allow the FDA to
    collect “records or other information” from facilities
    “in advance of, or in lieu of” inspections of
    manufacturing establishments. We will be monitoring for FDA’s
    guidance on this new authority. (US)

Coverage & Reimbursement

Whether Medicare/Medicaid or commercial payors are
willing to pay for a product, how much, and under what

  • Section 3630 of the
    Omnibus Spending Law
    codifies FDA’s previous guidance that
    permits pre-approval communication to payors and formulary
    committees about healthcare economics information related to
    unapproved products or unapproved uses of products. (US)


  • We continue to follow how the Inflation Reduction
    Act of 2022
    will impact reimbursement for pharma & biologic
    products (price caps, required discount program for all drugs,
    mandatory rebates if a drug’s price increases at a rate that
    outpaces inflation, and a redesign of the Medicare Part D benefit).
    We anticipate program instructions from CMS with respect to price
    caps for expensive single-source drugs and biologics in 2023. Some
    companies (for example, Eli Lilly) have already announced making
    pipeline changes based on the IRA’s effects. (US)

  • HHS has issued a new proposed rule
    that would modify the current alternative dispute resolution
    process under the 340B drug discount program, which has been the
    subject of much scrutiny and disagreement among pharmaceutical
    manufacturers (who are obligated to cap prices significantly for
    patients of qualified covered 340B public health entities) and the
    public health entities whose patients benefit from reduced 340B
    pricing. The proposed rule (which is open for comments until Jan.
    30, 2023) would simplify and expedite the process by which covered
    entities and drug manufacturers resolve disputes about
    overcharging, duplicate discounts, or drug diversion. (US)

Medical Device/Medtech

Compliance, Fraud & Abuse, Transparency

Companies’ interactions with their customers and
other stakeholders:

  • Shifts in DOJ Compliance
    and priorities – Compensation, Mobile Devices,
    Role of the Chief Compliance Officer – continue to be front
    of mind for our chief compliance officer clients. (US)

  • We are seeing continued increase in DOJ enforcement of the
    False Claims Act and Anti-Kickback Statute in laboratory,
    diagnostic testing, and telehealth spaces. (US)

Patient Privacy

Companies’ interactions with sensitive patient

*On December 29, 2022, President Biden signed the Consolidated Appropriations Act, 2023 (the
“Omnibus Spending Law”). We have highlighted below
several notable provisions from the Omnibus Spending Law, including
provisions derived from the Food & Drug Omnibus Reform Act
(FDORA) and the Pre-Approval Information Exchange Act (PIE)

The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.

POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States


Source link

Related posts

Growth In “buy Now, Pay Later” Financing Plans Raise Concerns Around Potential Consumer Harm – Dodd-Frank, Consumer Protection Act

Preventing Conflicts Of Interest – Corporate and Company Law

Anti-Abuse Exception To The Anti-Clawback Regulations (T.D. 9884) – Tax Authorities